


Shares of LB have rallied on Thursday morning as a result of the company announcing a surprise profit in the quarter and also raising guidance for the year to come. This could result in a massive rally in the days to come as the stock has lost 40% of value in 6 months and was actually down 5% yesterday prior to the earnings report. COMPANY PROFILE L Brands, Inc....
*****CONTINUATION LOOKS ON THE CARDS TODAY, STRONG GAINS THE AFTER HOURS ONCE AGAIN ON GOOD VOLUME . CURRENTLY ON RESISTANCE AT $18 A BREAK COULD BE VERY REWARDING. ***********NEWS FLOW********* The FDA designates Iovance Biotherapeutics' (NASDAQ:IOVA) LN-145 a Breakthrough Therapy for the treatment of recurrent, metastatic, or persistent cervical cancer that...
************************A CAVALCADE OF GOOD NEWS LATELY IN NASDAQ:NOVN HAS SPURNED A EPIC RALLY FROM LATE APRIL. NOT TO WORRY IF YOU HAVE NOT BEEN INVOLVED THERE IS PLENTY OF ACTION LEFT IN THIS NAME AS INSIDERS HAVE BEEN BUYING UP SHARES. A BREAK ABOVE $2.45 IS A GOOD BUY SIGNAL ON GOOD VOLUME ********************* On May 6, it announced that it sold the...
****** HUGE MOVE ON THE WAY TODAY, THIS COULD REALLY ROCKET HIGHER****************** Thinly traded micro cap Valeritas Holdings (NASDAQ:VLRX) is up 38% premarket on increased volume in reaction to new data from the VERDICT study, a real-world retrospective analysis of electronic medical records from a large diabetes center. Patients with HbA1c levels greater...
*****SPECULATION IS WE COULD GET A SIZEABLE MOVE IN THE STOCK TODAY WITH W EASY 30% GAIN********************* SET ALERTS FOR A POSSIBLE MOVE TO ABOVE $2 AVERAGE PRICE TARGET $9 AVERAGE RECOMMENDATION buy LEAP THERAPEUTICS INC. Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat...
*******STRONG BREAKOUT COMING**** Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug...
NASDAQ:USAT Shares of USA Technologies (NASDAQ: USAT) climbed 12% on Tuesday after hedge fund Hudson Executive Capital disclosed a 12% stake in the troubled networking and cashless transaction company, this is on the back of a terrible 2019 for the company. WE EXPECT SERIOUS CONTINUATION ABOVE $7 IT WILL RUN HARD. The stock price is at a a critical point- Sitting...
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oragenics Inc (OGEN) today and set a price target of $2. The company’s shares closed yesterday at $0.55, close to its 52-week low of $0.38. Selvaraju observed: “We believe the Phase 2 study could report top-line results in early 2020. If AG013 could significantly reduce the duration and lower the...
The month of MAY has been quite interesting for NASDAQ:TROV having released earnings that beat but revenue that missed, it followed this up by securing a capital raise with Lincoln Park Capital Funds, which adds additional working capital to move forward with it clinical development programs. Speculation and rumors are quite active in the social platforms...
The speculation regarding a possible buyout has gathered steam, but we are of the opinion that the $9 price is lower than what the company is actually worth. The stock has a very high short interest of 21% which has helped drive down the price from $16 a year earlier. Just 2 Hedge funds are in control of 30% of the shares with 1 of those funds Armatice, having...
*****WE KEEP ALERTS SET ON THIS NAME AND BUY ORDER IN PLACE, RUMOR HAS IT THERE IS A MOVE COMING SOON, WITH MASSIVE UPSIDE POTENTIAL****** James mc Carthy from MAxim recently maintained his buy rating and initiated a $3 price target citing. “Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the...
Agile Therapeutics has resubmitted its U.S. marketing application for contraceptive patch Twirla, this follows the company receiving a CRL in December 2017 citing the need for additional adhesion data. Keep this on the watch-list for today and they weeks to come. When this moves it will be fast and frantic. Analyst Rating Overweight. 3 Buy 2 Hold Agile...
This was a real winner yesterday and today is going to be the same, already up 12% pre market, we think there should be continuation in this name for days to come. Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer OUTLOOK THERAPEUTICS INC. Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm...
Experts and analysts are falling over one another to upgrade GBT so it is no surprise it has had a beautiful run in 2019. Don't worry if you have missed out this is just the start, as commercialization becomes a reality. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle...
We expect a sizable move in Scorpio Tankers in the coming days , analysts were already bullish on the stock and it has once again received a upgrade from JP Morgan to overweight with a $34 price target today. They shipping stocks have been in a bear market for many years but that has now changed. The chart of STNG has formed a lovely base and is now set to...
Xoma corp has just received some glowing recommendations, one of which is from H.C Wainwright analyst Joseph Pantginis who has a buy rating with a $30 price target. He wrote, "We reiterate our Buy rating and $30 target. We highlight that we currently omit the 38 undisclosed partnered assets at the company, and look to provide potential contribution once...
****UPDATE**** THIS WILL RUN HARD TODAY, MASSIVE POTENTIAL ON RUMOR OF NON BINDING AGREEMENT WITH POTENTIAL BUYER.
Container Store reported fourth-quarter profit of $15.88 million, or 33 cents a share, from a loss of $399,000, or a penny a share, a year earlier. Revenue rose 8.8% to $253.2 million while comparable store-sales gained 8.5%. Analysts surveyed by FactSet had forecast earnings of 30 cents a share on revenue of $243 million. Expect some analysts upgrades to follow...